Showing 5891-5900 of 7509 results for "".
- FDA Accepts Dermavant's NDA for Tapinarof Cream for the Treatment of Adults with Plaque Psoriasishttps://practicaldermatology.com/news/fda-accepts-dermavants-nda-for-tapinarof-cream-for-the-treatment-of-adults-with-plaque-psoriasis/2460886/The FDA has accepted Dermavant Sciences' New Drug Application (NDA) for tapinarof for the treatment of plaque psoriasis in adult patients. Tapinarof is an investigational, novel, therapeutic aryl hydrocarbon receptor modulating agent, in development as a once-daily, steroid-free and
- Vivacare Calls on Derms to Share Knowledge During Psoriasis Awareness Monthhttps://practicaldermatology.com/news/vivacare-calls-on-terms-to-share-knowledge-during-national-psoriasis-month/2460885/Dermatologists from around the country have contributed tips to Vivacare’s education resources and Physician Directory, and the company is inviting others to join in. In honor of Psoriasis Awareness Month, Vivacare is requesting dermatologists share insights regarding psoriasis and its trea
- Open-label Extension Study Shows Long-term Safety, Efficacy for UCB's Bimekizumab in PsOhttps://practicaldermatology.com/news/open-label-extension-study-shows-long-term-safety-efficacy-for-ucbs-bimekizumab-in-pso/2460883/New interim data from an open-label extension trial to assess the long-term safety, tolerability, and efficacy of bimekizumab show that the majority of patients who achieved complete or near complete skin clearance after 16 weeks of bimekizumab treatment maintained these responses through to
- Rinvoq Has Quicker Onset, Higher EASI Scores than Dupixent in Phase 3b Study of Adults with Atopic Dermatitishttps://practicaldermatology.com/news/rinvoq-bests-dupixent-in-phase-3b-study-of-adults-with-atopic-dermatitis/2460882/AbbVie’s JAK Inhibitor Rinvoq (upadacitinib) performed better than Dupixent (dupilumab) for primary and all ranked secondary endpoints in a phase 3b head-to-head study in adults with atopic dermatitis (AD), according to a
- ParaPRO’s Natroba for Scabies Now Availablehttps://practicaldermatology.com/news/parapros-natroba-for-scabies-now-available/2460877/ParaPRO’s Natroba (spinosad) Topical Suspension, 0.9% for scabies is now available. Natroba is the first new scabies drug to be approved by the U.S. Food and Drug Administration (FDA) in more than 30 years. Earlier this year, the company received FDA approval of its supp
- US FDA Approves Saphnelo for Lupushttps://practicaldermatology.com/news/us-fda-approves-saphnelo-for-lupus/2460876/The U.S. Food and Drug Administration (FDA) approved Saphnelo (anifrolumab-fnia) as a treatment for adults with systemic lupus erythematosus (SLE) who are receiving standard therapy. Developed by AstraZeneca, Saphnelo is a monoclonal antibody administered by intravenous (IV)
- Survey: Cleansing Habits of Americans Are Not Up to Dermatologist Standardshttps://practicaldermatology.com/news/survey-cleansing-habits-of-americans-are-not-up-to-dermatologist-standards/2460871/Fully 91 percent of consumers agree that cleansing is important, only 23 percent say that a dermatologist would be pleased with their facial cleansing habits, according to a new survey conducted by CeraVe of 2,000 U.S. adults aged 18-40. This is why this CeraVe is helping
- PASI-HD: Modification to PsO Severity Scale Aims at Mild-to-Moderate Diseasehttps://practicaldermatology.com/news/pasi-hd-modification-to-pso-severity-scale-aims-at-mild-to-moderate-disease/2460867/A new modification to the Psoriasis Area and Severity Index (PASI) aims to address limitations of the scale when used to assess mild-to-moderate disease. PASI-high discrimination (PASI-HD), designed to be used in clinical trials among patients for whom the areas of affected body surface are less
- Sunscreen Recall: J & J Pulls Five Sunscreens Due to Benzene Contaminationhttps://practicaldermatology.com/news/sunscreen-recall-j-j-pulls-five-sunscreens-due-to-benzene-contamination/2460865/Johnson & Johnson is recalling five Neutrogena and Aveeno aerosol sunscreens after finding low levels of benzene in some samples. The recalled sunscreen products include: AVEENO PROTECT + REFRESH aerosol sunscreen NEUTROGENA Beach Def
- News You Can Use: Hydrafacial Offers Monthly Scholarships for Connect Certification Programhttps://practicaldermatology.com/news/news-you-can-use-hydrafacial-offers-monthly-scholarships-for-connect-certification-program/2460863/HydraFacial is now offering a scholarships for their Connect certification program The Connect certification program comprises business building, marketing, cross-selling, social media, networking, mentoring, and leadership in a 3-level program that includes video assessments